Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In June 2015, he launched and incorporated IDEAYA Biosciences as its first employee and Chief Executive Officer and led the company’s IPO in May 2019 (NASDAQ: IDYA). From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, which he led through its acquisition by Bristol-Myers Squibb in April 2015, and then served as Chief Operating Officer at FLX Bio (renamed RAPT Therapeutics, NASDAQ: RAPT), a spinout of Flexus Biosciences.

Goodbay Technologies provides outsourced customer support for leading growth-oriented companies. Goodbay Technologies is more than just a call center company – they partner with clients to drive customer retention and increase their profitability. Goodbay is part call center, part management consulting. In Sapan's role, Sapan focuses on creating strategic alignment between Goodbay Technology's team and the clients that they serve

Andrew and George’s careers in the intersection of health-tech, life sciences and entrepreneurship showcases the complex and often contradictory incentives of players in the healthcare industry. Learn more about the hardships and complexities within health-tech entrepreneurship by listening to Andy and George’s stories about Proteus and their other health-tech ventures and what they learned from the experience.

Howard recently joined Ultragenyx, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, and is responsible for leading the company’s global finance, accounting, corporate strategy and investor relations functions. Howard received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.